Dr. Dario Rusciano (born in 1955)
completed his PhD in Cell and Molecular Biology at Pisa University (Italy) in
1979. He was involved as post-doc and project leader in basic research on the
organ specificity of cancer metastasis at the Sclavo pharmaceutical company of
Siena (Italy) from 1982 to 1989, and then at the Friedrich Miescher Institute
of Basel (Switzerland) until the year 2000. He then shifted his interests
towards translational research in ophthalmology, working as lab leader for the
next 7 years in SIFI, a pharmaceutical company based in Sicily (Italy), and
then at Sooft, another pharmaceutical company now owned by Fidia
Pharmaceuticals (Abano Terme, Italy), where he was appointed research
director for ophthalmology. He retired in 2022 and presently works as a
scientific consultant for different clients. Most recently, he resumed his
interest in oncology, updating his last project in precision oncology and
personalized tumor therapies by using essentially three levels of
analysis. He has authored over 100 papers
published in international refereed journals, and one book on the experimental
approaches in cancer metastasis (Elsevier, 2000: https://www.elsevier.com/books/cancer-metastasis-experimental-approaches/rusciano/978-0-444-82372-4). He is present on Research Gate (https://www.researchgate.net/search/publication?q=dario+rusciano)
and LinkedIn (Feed | LinkedIn).
Orcid access number: 0009-0009-4707-7949.
Dr. Dario Rusciano (born in 1955)
completed his PhD in Cell and Molecular Biology at Pisa University (Italy) in
1979. He was involved as post-doc and project leader in basic research on the
organ specificity of cancer metastasis at the Sclavo pharmaceutical company of
Siena (Italy) from 1982 to 1989, and then at the Friedrich Miescher Institute
of Basel (Switzerland) until the year 2000. He then shifted his interests
towards translational research in ophthalmology, working as lab leader for the
next 7 years in SIFI, a pharmaceutical company based in Sicily (Italy), and
then at Sooft, another pharmaceutical company now owned by Fidia
Pharmaceuticals (Abano Terme, Italy), where he was appointed research
director for ophthalmology. He retired in 2022 and presently works as a
scientific consultant for different clients. Most recently, he resumed his
interest in oncology, updating his last project in precision oncology and
personalized tumor therapies by using essentially three levels of
analysis. He has authored over 100 papers
published in international refereed journals, and one book on the experimental
approaches in cancer metastasis (Elsevier, 2000: https://www.elsevier.com/books/cancer-metastasis-experimental-approaches/rusciano/978-0-444-82372-4). He is present on Research Gate (https://www.researchgate.net/search/publication?q=dario+rusciano)
and LinkedIn (Feed | LinkedIn).
Orcid access number: 0009-0009-4707-7949.